Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Metsera Inc. raised $275 million in its IPO, selling 15.3 million shares for $18 each, according to a statement. It had offered 17.2 million shares for $15 to $17 each.

Following a flurry of activity in early 2025, the IPO scene has cooled in the wake of President Trump’s economic tremors.

Odyssey and Sionna have filed to carry out IPOs on the Nasdaq, following after Metsera and Maze, ... the start-up says the proceeds of the IPO will go towards phase 2a trials of OD-07656, ...

Odyssey first filed for an IPO in January alongside fellow Massachusetts biotech Sionna Therapeutics. The latter company pushed through with its offering, landing on the Nasdaq floor with $219.2 ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

Belrise Industries IPO allotment date is likely today, May 26, and the IPO listing date is expected to be on May 28. Belrise Industries shares will be listed on both the stock exchanges, BSE and NSE.

Belrise Industries IPO listing date is today, May 28. Ahead of the share listing, Belrise Industries IPO GMP today and analysts indicate a decent debut of shares in the Indian stock market ...

Get the latest Maze Therapeutics, Inc. ... Initial Data Expected in H2 2025 Raised $140 Million in Gross Proceeds in Upsized IPO in February 2025, ... Metsera, Maze secure combined $415 million in ...

Belrise Industries IPO News: Pune-based Belrise Industries' initial public offer (IPO), comprising fresh issuance to the tune of Rs 2,150 crore, is set to hit Dalal Street on Wednesday, May 21.

India Business News: The National Stock Exchange's IPO is nearing approval from Sebi. NSE, valued at Rs 4.7 lakh crore in 2024, dominates India's stock market and boasts o ...